Company investigating whether the illness may be a side effect of the vaccine
WEDNESDAY, Sept. 9, 2020 (HealthDay News) — A “potentially unexplained” illness in a participant has led AstraZeneca to halt a late-stage clinical trial of its COVID-19 vaccine.
The company is investigating whether the illness may be a side effect of the vaccine, the Associated Press reported. The pause in the study covers the United States and other countries where the vaccine is being tested. The health news site STAT said the possible side effect occurred in the United Kingdom, the AP reported.
“We are working to expedite the review of the single event to minimize any potential impact on the trial timeline,” AstraZeneca said in a statement.
Large, final-stage clinical trials of two other COVID-19 vaccines are underway in the United States, one from Moderna and the other from Pfizer and BioNTech. Those two vaccines work differently than the AstraZeneca vaccine, the AP reported.
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease
Trends Reported in Vaccination Coverage for Adolescents for 2025
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer
Retinal Imaging Can ID Atrial Fibrillation Years Before Diagnosis
U.S. Adults May Not Understand Their Risk for Vascular Disease
Lower Breast, Cervical Cancer Screening Seen for Adults With Disabilities
Screening + Online Cognitive Behavioral Therapy Program Aids Nurses" Mental Health